Brought to you by 
Sanofi to acquire BiPar Sciences
Apr 2009
Executive Summary
Sanofi-Aventis has acquired privately held BiPar Sciences (cancer therapeutics) in an all-cash deal that IN VIVO believes consisted of a $375mm up-front payment and the potential for another $125mm in earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Includes Earnout
- Acquisition of Private Biotech
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com